ArticleBlood cancer journal2025

Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients.

Paul J Hengeveld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.